Back

Oral procainamide as pharmacological treatment of recurrent and refractory ventricular tachyarrhythmias

23 April 2021 (14:00 - 21:00)
Organised by:
Congress Presentation Part of: ePoster session Antiarrhythmic Drug Treatment EHRA Premium Access EHRA 2021

About the speaker

Photo
Doctor Mauro Toniolo

Hospital Santa Maria della Misericordia, Udine (Italy)

286 More presentations in this session

Presentation thumbnail
Non-valvular atrial fibrillation recurrence after sinus rhythm restoring at different follow-up periods: phenotype-genotype high-risk groups, considering rs10465885 polymorphism in connexin-40 gene
Doctor T. Mikhalieva (Kyiv, UA)
Abstract Slides
Presentation thumbnail
Atrial fibrillation substrate mapping with decrement evoked potential mapping.
Doctor O. Salvador (Parla, ES)
Abstract Slides
Presentation thumbnail
Atrial tissue characterization by cardiac magnetic resonance and high-density mapping in patients with atrial fibrillation
Miss R. Adelino Recasens (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Proarrhythmic atrial structural and molecular remodeling with advancing age. Implications for post-coronary artery bypass grafting atrial fibrillation occurrence.
Doctor R. SERBAN (Targu Mures, RO)
Abstract Slides
Presentation thumbnail
Find me if you can: lessons learned using the novel cartofinder algorithm in a routine workflow for catheter ablation of atrial fibrillation
Doctor C. Sohns (Bad Oeynhausen, DE)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

EHRA 2021

23 April 2021 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Comparison between oral procainamide and mexiletine for the treatment of recurrent and refractory ventricular tachyarrhythmias.
4 April 2022
thumbnail
Congress Presentation
Clinical and anamnestic features of patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death
29 June 2021
thumbnail
Congress Presentation
The administration of valproic acid exerts a protective effect by reducing the infarct size and the triggering of ventricular fibrillation in an experimental model of chronic myocardial infarction
28 August 2022
thumbnail
Congress Session
The storm will pass…
31 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources